Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 824 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR AI is impacting cancer care, but also the environment September 25, 2025 How My Cancer Diagnosis Has Fueled My Work in Improving Access... December 19, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin July 29, 2020 EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib July 3, 2020 Load more HOT NEWS Young Boy Wears Shirt That Says ‘I Will Be Your Friend’... Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... What You Should Know About Receiving Online Medical Test Results and... How Alcohol Increases Your Cancer Risk and What to Know About...
